---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-162056"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:08:37.066665+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mirum reports positive interim Ph2b data for volixibat in PBC and PSC

## Summary
- VANTAGE PBC trial: volixibat achieved placebo-adjusted -2.32 point itch reduction (p=0.0026); 75% of patients had >50% drop in serum bile acids.
- Significant fatigue improvement at week 16; no new safety signals; diarrhea (77%) mostly mild/moderate and transient; 4 SAEs (1 placebo).
- VANTAGE and VISTAS PSC trials to continue with volixibat 20 mg twice daily; independent data review committee recommended continuation for PSC.
- No clinically meaningful changes in liver biomarkers in PBC; sponsor remains blinded to interim results.

## SEC filing metadata
- accession: 0001193125-24-162056
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312524162056/0001193125-24-162056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312524162056/d853346d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-162056
- JSON: https://secwatch.observer/filing/0001193125-24-162056.json
- Plain text: https://secwatch.observer/filing/0001193125-24-162056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.